Stockscreener 앱 받기
5.12
2.29%
-0.12
시간 외 거래:
5.14
0.02
+0.39%
Savara Inc 주식(SVRA)의 최신 뉴스
SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN
Savara Grants Equity Awards to 24 New Employees - MyChesCo
US High Growth Tech Stocks To Watch - Sahm
Savara Inc. ticks higher amid takeover speculation - MSN
FDA Extends Review of Savara’s Molgramostim Application to November - MyChesCo
Savara to Present Molgramostim Data at ATS 2026 Conference - MyChesCo
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Yahoo Finance
Savara’s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed - Sahm
Savara Inc ($SVRA) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Savara Inc SEC Filing - Stock Titan
Savara (NASDAQ: SVRA) seeks big share boost and equity plan expansion - Stock Titan
Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Savara (SVRA) Stock: Pricing Efficiency Review | Q4 2025: EPS Misses EstimatesLow Growth - Cổng thông tin điện tử tỉnh Lào Cai
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Savara (SVRA) Stock: Why It Could Double (Mini Selloff) 2026-04-20Profit Potential - Cổng thông tin điện tử tỉnh Lào Cai
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
Savara Announces New Employment Inducement GrantApril 17, 2026 - BioSpace
FY2026 EPS Estimates for Savara Decreased by Lifesci Capital - MarketBeat
Savara Inc stock (US80633A1025): Why does its rare disease focus matter more now for investors? - AD HOC NEWS
Savara Says UK Regulator Accepts MOLBREEVI Application - MyChesCo
Savara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech Segment - Kalkine Media
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Savara (NASDAQ:SVRA) Stock Price Up 2.5%Here's Why - MarketBeat
How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP - simplywall.st
FDA extends review of Savara’s molgramostim application By Investing.com - Investing.com India
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 91.71% Potential Upside - DirectorsTalk Interviews
Savara (SVRA) Receives FDA Review Extension for Molgramostim App - GuruFocus
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $9 - Moomoo
Savara gets FDA review extension for lead asset - MSN
Savara gets FDA review extension for lead asset (SVRA:NASDAQ) - Seeking Alpha
Savara (SVRA) Receives Three-Month Extension for BLA Review - GuruFocus
FDA Extends Review Period for Savara's Molgramostim BLA in Autoimmune PAP - National Today
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
FDA extends review of Savara’s molgramostim application - Investing.com
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits
Savara to present molgramostim data at ATS conference in May - Investing.com
2.45%
자본화:
|
볼륨(24시간):